Lunai Bioworks Inc.

Pre-revenue biotech with explicit going-concern doubt, a bankrupt subsidiary, and almost no cash.

Strengths

• Recent debt restructuring eliminated $9.7M of secured notes via equity conversion
• AI cancer-diagnostics platform refocus could attract future funding

Risks

• Going concern: only $92,700 cash, current ratio 0.036 (2nd pct), $510M accumulated deficit, $29.6M liabilities
• Indirect subsidiary (Gedi Cube B.V.) declared bankrupt; ROE 8.3x is a negative-equity artifact, ROA -21.6

Notable findings

• Going concernThese conditions raise substantial doubt about our ability to continue as a going concern for one year after the date the financial statements are issued
• Weak liquidityCurrent ratio 0.04 (<1)
• Chronic dilutionShare count +36%/yr over 2y (dilution, book value/share -125%)
• Revenue declineRevenue -100.0% YoY